Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)
Over the last decade, genomics and proteomics have been used as key tools to discover potential drug targets and to better understand the complexities of biology. To balance research in these areas, epigenetics offers a potential opportunity in understanding the basis of various diseases in a different approach. Thus, epigenetics is study of heritable changes in genome function and gene expression had opened the new gate of biology to understand the basis of diseases and presents incredible opportunities for disease diagnosis and drug discovery.
Report covers the market by therapeutics sector in oncology conditions, non-oncology indications and personalized medicine. The report also covers the market by research and diagnostics sector in gene regulation studies, biomarker detection and drug discovery. In addition, it also includes the factors driving and restraining the market and covers the market scenario in the U.S., Europe, Asia and the Rest of the World (ROW). This report will provide the company profiles of key companies along with the competitive analysis.
The Global Epigenetics market is showing a double digit growth (CAGR 25%) due to supportive factors such as, (i) huge amount of funds and investments, (ii) increasing partnerships and collaborations, and (iii) rapid screening tools. Epigenetics is used in the identification of new epigenetic biomarkers, which will aid in better diagnosis and prognosis of diseases. While there are factors favoring the market growth, there are concerns such as change in re-imbursement systems and lack of predictive markers holding back the growth of this market. However, the positive aspects in this field may very well offset the market restraints to aid the market grow at an exceptional rate.
The report also profiles leading participants of this industry with their recent developments and other strategic industry activities. These include: CH3 BioSystems (U.S.), Eisai (Japan), Covaris Inc. (U.S.), Epiontis (Germany), RiboMed Biotechnologies (U.S.), 4SC (Germany), Merck Millipore (U.S.), CellCentric (U.K.), Celgene (U.S.), Karus Therapeutics (U.K.), EpiTherapeutics (Denmark), Epizyme (U.S.)
Scope of the Report
- This technology report categorizes the market for epigenetics by geographical region (including the important countries in each region), applications, and epigenetic mechanisms, forecasting the market value in revenue by analyzing the current and future trends in research, diagnostics and therapeutics industries.
- A detailed description of the global technology developments and evolving trends in the epigenetics field with key prominence on research innovations, collaborative efforts and focused research through consortiums dedicated for epigenetics.
- A close view on the drug development for treatment of various diseases by providing the details and status of current epigenetic drugs in pipeline.
- An impact analysis of major drivers, restraints and challenges influencing the adoption and growth of epigenetics market during the period from 2012 to 2017.
- Market size - Global market forecast for 2012-2017, including demand side analysis and strategic recommendations for technology/product developers.
- Competitive landscape based on the analysis of key patents and research publications that gives an insight into prominent activities and global participants.
TABLE OF CONTENTS:
1.1 KEY TAKE-AWAYS
1.2 REPORT SCOPE
1.3 RESEARCH METHODOLOGY
1.4 KEY DATA POINTS FROM PRIMARY AND SECONDARY SOURCES
2 EXECUTIVE SUMMARY
3 EPIGENETICS – TECHNOLOGY LANDSCAPE ANALYSIS
3.1 TECHNOLOGY OVERVIEW
3.2 TECHNOLOGY EVOLUTION – MILESTONES IN EPIGENETICS
3.3 EPIGENETIC MECHANISMS
3.3.1 DNA METHYLATION
3.3.2 HISTONE MODIFICATIONS
3.3.3 RNA INTERFERENCE
3.4 TECHNOLOGY VALUE CHAIN ANALYSIS
22.214.171.124 ONCOLOGY CONDITIONS
126.96.36.199 NON-ONCOLOGY INDICATIONS
188.8.131.52 PERSONALIZED MEDICINE
3.5.2 RESEARCH AND DIAGNOSTICS
184.108.40.206 GENE REGULATION STUDIES
220.127.116.11 BIOMARKER DETECTION
18.104.22.168 DRUG DISCOVERY
3.6 EPIGENETICS – TECHNOLOGY INNOVATIONS AND PRODUCTS WITH APPLICATIONS
3.7 CURRENT SCENARIO IN EPIGENETICS
4 EPIGENETICS – MARKET LANDSCAPE ANALYSIS
4.1 EPIGENETICS MARKET SIZE – POTENTIAL ADDRESSABLE MARKET
4.2 GLOBAL EPIGENETICS MARKET SEGMENTATION
4.3 GLOBAL MARKET REVENUE FORECAST (2012-2017)
4.3.1 BY GEOGRAPHY
4.3.2 BY APPLICATIONS
4.3.3 BY EPIGENETIC MECHANISMS
4.4 MARKET SHARE OF COMPANIES
4.5 MARKET DYNAMICS
5 TECHNOLOGY INVESTMENT POTENTIAL
5.1 INVESTOR NETWORK
5.1.1 SOME FUNDS AND INVESTMENTS BY PUBLIC FUNDING BODIES
5.1.2 SOME FUNDS AND INVESTMENTS BY NON-GOVERNMENT ORGANIZATIONS (NGOs)
5.1.3 SOME INVESTMENTS BY CORPORATE, PRIVATE AND EQUITY INVESTORS
5.1.4 INSIGHTS ON CURRENT AND FUTURE TECH-INVESTMENT TRENDS
5.1.5 FUNDING PATTERNS AND INVESTOR INCLINATION
5.2 INVESTMENT OPPORTUNITIES
5.2.1 EPIGENETIC TECHNOLOGIES AND PRODUCTS AVAILABLE FOR LICENSING & ACQUISITION FOR STAKEHOLDERS
5.2.2 ANALYSIS OF POTENTIAL APPLICATION AREAS FOR TECHNOLOGY INVESTMENT – BASED ON OPPORTUNITY STRATEGY EVALUATION (OSE) ANALYSIS
6 EPIGENETICS – TECHNOLOGY ADOPTION POTENTIAL AND DEVELOPMENT BY GEOGRAPHY
6.2 NORTH AMERICA
6.6 DEMAND SIDE ANALYSIS
7 EPIGENETICS COMPETITIVE LANDSCAPE
7.1 KEY MERGERS AND ACQUISITIONS
7.2 PARTNERSHIPS AND COLLABORATIONS
7.3 THERAPEUTIC DRUGS IN PIPELINE
7.4 WORLDWIDE CONSORTIUMS AND NETWORKS IN EPIGENETICS
8 INTELLECTUAL PROPERTY AND RESEARCH STRENGTH ANALYSIS
8.1 IP STRENGTH ANALYSIS OF EPIGENETICS BETWEEN 2008-2012
8.2 ANALYSIS OF RESEARCH STRENGTH FROM NCBI PUBMED PUBLICATIONS
9 ANALYST INSIGHTS AND RECOMMENDATIONS
9.1 ANALYST INSIGHTS
9.2 ANALYST RECOMMENDATIONS
9.3 OPEN OPPORTUNITY INVITATIONS IN THE FIELD FOR BUSINESS DEVELOPMENT
10 COMPANY PROFILES
10.1 4SC (GERMANY)
10.2 CELGENE (U.S.)
10.3 CELLCENTRIC (U.K.)
10.4 CH3 BIOSYSTEMS (U.S.)
10.5 COVARIS INC (U.S.)
10.6 EISAI CO LTD (JAPAN)
10.7 EPIONTIS (GERMANY)
10.8 EPITHERAPEUTICS (DENMARK)
10.9 EPIZYME (U.S.)
10.10 KARUS THERAPEUTICS (U.K.)
10.11 MERCK MILLIPORE (U.S.)
10.12 RIBOMED BIOTECHNOLOGIES (U.S.)
LIST OF TABLES
TABLE 1 GLOBAL EPIGENETICS MARKET REVENUE, BY GEOGRAPHY, 2012–2017 ($MILLION)
TABLE 2 GLOBAL EPIGENETICS MARKET REVENUE, BY APPLICATION SEGMENTS, 2012–2017 ($MILLION)
TABLE 3 GLOBAL EPIGENETICS MARKET REVENUE, BY THERAPEUTIC APPLICATIONS, 2012–2017 ($MILLION)
TABLE 4 GLOBAL EPIGENETICS MARKET REVENUE, BY RESEARCH & DIAGNOSTICS APPLICATIONS, 2012–2017 ($MILLION)
TABLE 5 GLOBAL EPIGENETICS MARKET REVENUE, BY EPIGENETIC MECHANISMS, 2012–2017 ($MILLION)
TABLE 6 MARKET SHARE OF COMPANIES BASED ON CURRENTLY AVAILABLE FOUR DRUGS
TABLE 7 SOME FUNDS AND INVESTMENTS BY PUBLIC FUNDING BODIES
TABLE 8 EPIDEMIOLOGY AND GENOMICS RESEARCH PROGRAM (EGRP) FUNDING DETAILS FOR EPIGENETICS
TABLE 9 NIH FUNDING DETAILS FOR EPIGENETICS
TABLE 10 SOME FUNDS AND INVESTMENTS BY NON-GOVERNMENT ORGANIZATIONS (NGOS)
TABLE 11 SOME INVESTMENTS BY CORPORATE, PRIVATE AND EQUITY INVESTORS
TABLE 12 WORLDWIDE INCIDENCE & MORTALITY OF SELECTED CANCERS (CASES/YEAR)
TABLE 13 MERGERS AND ACQUISITIONS
TABLE 14 PARTNERSHIPS AND COLLABORATIONS
TABLE 15 THERAPEUTIC DRUGS IN PIPELINE
TABLE 16 KEY PATENTS
TABLE 17 DIFFERENT TYPES OF PRODUCTS FOR EPIGENETIC MECHANISMS – DNA METHYLATION
TABLE 18 DIFFERENT TYPES OF PRODUCTS FOR EPIGENETIC MECHANISMS – HISTONE MODIFICATIONS
TABLE 19 DIFFERENT TYPES OF PRODUCTS FOR EPIGENETIC MECHANISMS – RNA INTERFERENCE
LIST OF FIGURES
FIG 1 GLOBAL MARKET OF EPIGENETICS 2012–2017 ($MILLION)
FIG 2 GLOBAL EPIGENETICS MARKET REVENUE, BY GEOGRAPHY, 2012–2017 ($MILLION)
FIG 3 GLOBAL EPIGENETICS MARKET SHARE – BY GEOGRAPHY
FIG 4 GLOBAL EPIGENETICS MARKET REVENUE, BY APPLICATION SEGMENTS,2012-2017 ($MILLION)
FIG 5 GLOBAL EPIGENETICS MARKET REVENUE, BY THERAPEUTIC APPLICATIONS, 2012–2017 ($MILLION)
FIG 6 GLOBAL EPIGENETICS MARKET REVENUE, BY RESEARCH & DIAGNOSTICS APPLICATIONS, 2012–2017 ($MILLION)
FIG 7 GLOBAL EPIGENETICS MARKET SHARE – BY APPLICATIONS
FIG 8 GLOBAL EPIGENETICS MARKET REVENUE, BY EPIGENETIC MECHANISMS, 2012–2017 ($MILLION)
FIG 9 MARKET SHARE OF COMPANIES BASED ON CURRENTLY AVAILABLE FOUR DRUGS
FIG 10 EPIDEMIOLOGY AND GENOMICS RESEARCH PROGRAM (EGRP) FUNDING DETAILS FOR EPIGENETICS
FIG 11 NIH FUNDING DETAILS FOR EPIGENETICS
FIG 12 EPIGENETICS, YEAR-WISE FUNDING PATTERNS & INVESTMENT FORECAST (2012–2017)
FIG 13 CURRENT FUNDING PATTERN BY INVESTORS FOR EPIGENETICS
FIG 14 PATENTS PUBLISHED BETWEEN 2008-2012
FIG 15 PUBMED PUBLICATIONS BETWEEN 2008-2012
FIG 16 PUBMED PUBLICATIONS ON EPIGENETIC ENZYMES 2008-2012
Epigenetics is one of the fastest emerging scientific field with promising growth potential to revolutionize therapeutics and diagnostics industries in healthcare. It is the scientific study of heritable changes in genome function and gene expression had opened the new gate of biology to understand the basis of diseases and presents incredible opportunities for disease diagnosis and drug discovery.
Epigenetics field has been greatly attracted by the research and pharmaceutical industries as epigenetic changes are mostly reversible unlike the permanent mutations and appears to be promising to provide new prospects in cancer therapeutics. The field of epigenetics is currently growing at a rapid pace in cancer therapeutics which is evident from the revenue generated through the sales of the approved four epigenetic based drugs for cancer.
The current global epigenetics market is estimated as $2.6 Billion and is expected to reach $8 Billion by the year 2017, growing at a CAGR of 25%.
The rapid growth of epigenetics field is attributed due to its promising research in cancer therapeutics and its extension in non-oncology indications such as autoimmune diseases, inflammatory diseases, neurological disorders, etc. will further enhance its market growth. Currently, there are around 40 drugs in pipeline, developed by various pharmaceutical companies targeting various cancers and non-oncology indications. The current approach of epigenetics in targeted therapy and personalized medicine for cancer has the potential to address the demands in the healthcare industry.
Owing to the great prospects of epigenetics in therapeutic industry, a lot of investments are made by the private investors to support small pharma companies with strong research in epigenetics. The extensive efforts to understand and innovate in the field of epigenetics can be observed by formation of consortiums exclusively for epigenetics research and developments, involving the academic researchers and pharmaceutical industries.
Based on geographical regions, currently North America dominates with 40% of market share, followed by Europe with 36%. However in future, countries in Asia-Pacific region will greatly drive the growth of epigenetics market in future owing to the favorable regulatory landscape, increased population with cancer, diabetes, cardiovascular diseases, etc. and rising disposable incomes.
The key participants in the global epigenetic market are CELGENE (U.S.), MERCK (U.S.), EISAI (JAPAN), EPIZYME (U.S.), 4SC (GERMANY), NOVARTIS (SWITZERLAND), CELLCENTRIC (U.K.), EPITHERAPEUTICS (DENMARK), CH3 BIOSYSTEMS (U.S.), RIBOMED BIOTECHNOLOGIES (U.S.), COVARIS INC. (U.S.), MERCK MILLIPORE (U.S.), EPIONTIS (GERMANY).